ADRB3 and neoplasm: Here, we demonstrated that pharmacological antagonism of β3-AR by using SR59230A induced a multi-lineage commitment of the HSCs recruited in the tumor microenvironment, and partially in the bone marrow niche, and that this effect impairs stromal cells sustainability to tumor progression.